AUTOIMMUNE HEMOLYTIC ANEMIA
Clinical trials for AUTOIMMUNE HEMOLYTIC ANEMIA explained in plain language.
Never miss a new study
Get alerted when new AUTOIMMUNE HEMOLYTIC ANEMIA trials appear
Sign up with your email to follow new studies for AUTOIMMUNE HEMOLYTIC ANEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on rare blood disorders
Disease control Not yet recruitingThis phase 2 trial tests a personalized CAR T cell therapy called zolacabtagene autoleucel in 52 adults with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The treatment uses the patient's own immune cells, modified to target and destroy faulty B cel…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental CAR-T therapy takes on stubborn blood disorder
Disease control Not yet recruitingThis early-phase study tests a new treatment called IASO206 for people whose autoimmune hemolytic anemia (AIHA) has not responded to standard therapies. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing fatigue and other symptoms. The study …
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cell therapy offers hope for tough anemia cases
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after at least three prior treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the anemia. The …
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
MRNA technology takes on autoimmune diseases in new trial
Disease control Not yet recruitingThis early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cell therapy takes on tough blood disorder
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called YTS109 in 13 adults with autoimmune hemolytic anemia that has not responded to at least three prior treatments. The therapy uses specially engineered immune cells to target and control the disease. The main goals are to check…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug enatumab tested for tough blood disorder
Disease control Not yet recruitingThis phase 2 trial is testing a drug called enatumab in 3 adults with relapsed or refractory warm antibody autoimmune hemolytic anemia (wAIHA), a condition where the immune system destroys red blood cells. Current treatments often stop working or cause relapses. Enatumab is given…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE2 • Sponsor: Bing Han • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare blood disorder: linprixel trial launches
Disease control Not yet recruitingThis phase 2 trial tests linprixel, a daily pill, in 22 adults with relapsed or refractory autoimmune hemolytic anemia (AIHA). The study aims to see if the drug can improve red blood cell counts after 12 weeks. Participants start at 40mg daily, with possible dose increases if nee…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:46 UTC